Clozapine should be initiated at 25 mg once or twice daily with gradual titration

The patient must be enrolled in the Clozapine REMS program with ANC monitoring weekly for the first six months, then biweekly for six months, and monthly thereafter if counts remain within acceptable ranges. Concurrent metabolic monitoring including fasting glucose, lipid panels, and weight should be planned at regular intervals given the high metabolic risk associated with clozapine. Baseline echocardiography and ongoing cardiac monitoring should be discussed due to the risk of myocarditis, particularly during the first month of treatment. The PMHNP should plan for slow titration to a target range typically between 300 and 450 mg daily, with clozapine serum levels guiding dose optimization toward a therapeutic threshold of 350 ng/mL.

Clozapine should be initiated at 100 mg daily to achieve therapeutic levels rapidly

As the primary risk with clozapine is prolonged subtherapeutic dosing that fails to address the patient's persistent psychotic symptoms. ANC monitoring is required monthly from the outset because the risk of agranulocytosis is evenly distributed throughout treatment and does not vary based on duration of exposure. Metabolic monitoring can be deferred for the first three months until steady-state dosing is established, since metabolic changes do not emerge until clozapine reaches therapeutic serum concentrations. The target serum level should be at least 500 ng/mL, as lower levels are consistently associated with inadequate antipsychotic response in treatment-resistant populations.

Before initiating clozapine, the patient must first complete an adequate trial of a first-generation antipsychotic such as haloperidol

Because treatment-resistance criteria require failure of both typical and atypical antipsychotic classes before clozapine can be prescribed. The Clozapine REMS program requires baseline and weekly complete blood counts with differential for the entire duration of treatment, without any reduction in monitoring frequency regardless of time on treatment. Clozapine should be started at 25 mg daily and titrated rapidly to 400 mg within the first two weeks to minimize the duration of subtherapeutic dosing. Routine EEG monitoring should be initiated concurrently because clozapine lowers the seizure threshold at all doses, and prophylactic valproic acid should be co-prescribed from the outset.

Clozapine initiation should be delayed until the patient's ANC exceeds 3,500 cells/microL

As the REMS program requires a higher baseline threshold to ensure adequate neutrophil reserve before exposure to a medication with agranulocytosis risk. The initial dose should be 12.5 mg daily with titration every three days, and ANC monitoring should occur twice weekly for the first month, then weekly for the remainder of the first year, reflecting the highest-risk period for hematological complications. Metabolic monitoring should include quarterly HbA1c, fasting lipids, and waist circumference measurements, and the patient should be switched from any concurrent antipsychotic immediately upon clozapine initiation. The target dose range is 200 to 300 mg daily, as higher doses provide no additional efficacy and substantially increase the risk of metabolic syndrome.